Gene expression profiling in diffuse large B-cell lymphona

Daniel Morgensztern, Michael Martin, Izidore S. Lossos

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Diffuse Large B cell lymphoma (DLBCL) is characterized by a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histopathologic and immunophenotypic evaluations. Analysis of global gene expression using DNA microarrays has the potential to improve the classification of lymphomas. Molecular profiling may allow the description of specific disease subtypes with similar clinical behavior and outcome. In addition, gene expression profiling has led to the discovery of new putative genes and a better understanding of aberrant signaling pathways. These insights may lead to the discovery of new targeted therapies. This review describes the progress that has been made in our understanding of DLBCL as a result of gene expression profiling.

Original languageEnglish (US)
Pages (from-to)669-682
Number of pages14
JournalLeukemia and Lymphoma
Volume48
Issue number4
DOIs
StatePublished - Apr 1 2007
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Gene Expression Profiling
B-Lymphocytes
Oligonucleotide Array Sequence Analysis
Lymphoma
Gene Expression
Therapeutics
Genes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Gene expression profiling in diffuse large B-cell lymphona. / Morgensztern, Daniel; Martin, Michael; Lossos, Izidore S.

In: Leukemia and Lymphoma, Vol. 48, No. 4, 01.04.2007, p. 669-682.

Research output: Contribution to journalReview article

Morgensztern, Daniel ; Martin, Michael ; Lossos, Izidore S. / Gene expression profiling in diffuse large B-cell lymphona. In: Leukemia and Lymphoma. 2007 ; Vol. 48, No. 4. pp. 669-682.
@article{6234ea770c094d66962b3f12050f439b,
title = "Gene expression profiling in diffuse large B-cell lymphona",
abstract = "Diffuse Large B cell lymphoma (DLBCL) is characterized by a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histopathologic and immunophenotypic evaluations. Analysis of global gene expression using DNA microarrays has the potential to improve the classification of lymphomas. Molecular profiling may allow the description of specific disease subtypes with similar clinical behavior and outcome. In addition, gene expression profiling has led to the discovery of new putative genes and a better understanding of aberrant signaling pathways. These insights may lead to the discovery of new targeted therapies. This review describes the progress that has been made in our understanding of DLBCL as a result of gene expression profiling.",
author = "Daniel Morgensztern and Michael Martin and Lossos, {Izidore S.}",
year = "2007",
month = "4",
day = "1",
doi = "10.1080/10428190601186176",
language = "English (US)",
volume = "48",
pages = "669--682",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Gene expression profiling in diffuse large B-cell lymphona

AU - Morgensztern, Daniel

AU - Martin, Michael

AU - Lossos, Izidore S.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Diffuse Large B cell lymphoma (DLBCL) is characterized by a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histopathologic and immunophenotypic evaluations. Analysis of global gene expression using DNA microarrays has the potential to improve the classification of lymphomas. Molecular profiling may allow the description of specific disease subtypes with similar clinical behavior and outcome. In addition, gene expression profiling has led to the discovery of new putative genes and a better understanding of aberrant signaling pathways. These insights may lead to the discovery of new targeted therapies. This review describes the progress that has been made in our understanding of DLBCL as a result of gene expression profiling.

AB - Diffuse Large B cell lymphoma (DLBCL) is characterized by a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histopathologic and immunophenotypic evaluations. Analysis of global gene expression using DNA microarrays has the potential to improve the classification of lymphomas. Molecular profiling may allow the description of specific disease subtypes with similar clinical behavior and outcome. In addition, gene expression profiling has led to the discovery of new putative genes and a better understanding of aberrant signaling pathways. These insights may lead to the discovery of new targeted therapies. This review describes the progress that has been made in our understanding of DLBCL as a result of gene expression profiling.

UR - http://www.scopus.com/inward/record.url?scp=34247244740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247244740&partnerID=8YFLogxK

U2 - 10.1080/10428190601186176

DO - 10.1080/10428190601186176

M3 - Review article

VL - 48

SP - 669

EP - 682

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -